Blood cancers, Cell type, Low grade lymphoma, Lymphoma, Non-Hodgkin lymphoma (NHL)
Results
Phase 3
This trial looked at chlorambucil and rituximab as treatment for MALT lymphoma. You may have either drug on its own, or both drugs together.
MALT stands for mucosa associated lymphoid tissue. MALT lymphoma is a low grade, B cell, non Hodgkin lymphoma (NHL). Doctors usually use a chemotherapy drug called chlorambucil to treat MALT lymphoma. This shrinks the lymphoma in most cases, but it doesn’t usually go away completely.
Doctors thought that a monoclonal antibody called rituximab may have been useful. Trials in some other types of lymphoma have shown that rituximab and chemotherapy work well together. But doctors were not sure how well rituximab would work for MALT lymphoma, either on its own, or with chemotherapy.
In this trial, some people had chlorambucil, some people had rituximab and some had both drugs. The aim of the trial was to find out which of these 3 treatments worked best.
Recruitment start: 1 August 2003
Recruitment end: 9 June 2010
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Johnson
Experimental Cancer Medicine Centre (ECMC)
National Cancer Research Institute (NCRI)
National Institute for Health Research Cancer Research Network (NCRN)
University Hospital Southampton NHS Foundation Trust
Last reviewed: 12 Jan 2016
CRUK internal database number: 373